Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioInvent International AB ( (SE:BINV) ) just unveiled an update.
BioInvent International AB announced that it will present early Phase 2a data from its ongoing trial of a triple combination therapy involving BI-1206, rituximab, and Calquence for treating non-Hodgkin’s lymphoma (NHL) at the ASH 2025 meeting. The data indicates that the combination is safe and well-tolerated, with promising efficacy signals, and the company is optimistic about advancing to the next phase to potentially improve patient outcomes and the standard of care.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK34.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company that focuses on discovering and developing novel first-in-class immuno-modulatory antibodies for cancer therapy. The company is involved in Phase 1/2 trials for hematological cancers and solid tumors, utilizing its proprietary F.I.R.S.T™ technology platform to identify promising new candidates. BioInvent generates revenue through research collaborations, license agreements, and antibody production for third parties.
YTD Price Performance: -17.27%
Average Trading Volume: 98,276
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.1B
Learn more about BINV stock on TipRanks’ Stock Analysis page.